...this alone will meaningfully disfavor investment in biotech over other industries,” Akkaraju said via email. WBB Securities’...

...far-reaching, the implications are so far-reaching, like never before. That’s the reality we face,” said WBB Securities’...

...in 3Q19 have at least made it into the clinic, with Viela Bio nearing commercialization. WBB Securities’...

...fatten a queue that is growing again following a late-summer lull. “We’re seeing more IPOs,” WBB Securities'...

...way they have pushed the boundaries of what we've seen in biotech." Steve Brozak of WBB Securities...

...way they have pushed the boundaries of what we've seen in biotech." Steve Brozak of WBB Securities...

...underwritten by Ladenburg, Nomura, H.C. Wainwright, LifeSci Capital, Ascendiant Capital, SMBC Nikko Securities America and WBB Securities...

...provide a retention pool of $60 million for employees to be paid over five years. WBB Securities’...

...is going well and access is good,” said Staijen. John Nolan and Steve Brozak of WBB Securities...

...there’s a fear they could overpay.” John Nolan, WBB John Nolan and Steve Brozak of WBB Securities...